Abstract
Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments
Objective: To ease economic burdens for drug developers and general patient populations. Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested. Results: Drug development chains must be updated and better drug development paradigms must be established. Conclusions: This world welcomes global participations in anticancer drug developments and utilities.Keywords: Anticancer drug development, neoplasm metastasis, cost-effective, medicinal chemistry, animal models, drug toxicity, cancer stem cells, individualized cancer therapy.
Current Drug Therapy
Title:Anticancer Drug Development, System Updating and Global Participations
Volume: 12 Issue: 1
Author(s): Da-Yong Lu*, Ting-Ren Lu, En-Hong Chen, Nagendra Sastry Yarla, Bin Xu, Jian Ding and Hong Zhu
Affiliation:
- School of Life Sciences, Shanghai University, Shanghai 200444,China
Keywords: Anticancer drug development, neoplasm metastasis, cost-effective, medicinal chemistry, animal models, drug toxicity, cancer stem cells, individualized cancer therapy.
Abstract: Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments
Objective: To ease economic burdens for drug developers and general patient populations. Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested. Results: Drug development chains must be updated and better drug development paradigms must be established. Conclusions: This world welcomes global participations in anticancer drug developments and utilities.Export Options
About this article
Cite this article as:
Lu Da-Yong*, Lu Ting-Ren, Chen En-Hong, Yarla Sastry Nagendra, Xu Bin, Ding Jian and Zhu Hong, Anticancer Drug Development, System Updating and Global Participations, Current Drug Therapy 2017; 12 (1) . https://dx.doi.org/10.2174/1574885511666161025122906
DOI https://dx.doi.org/10.2174/1574885511666161025122906 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design The Concept of Phenoptosis and its Usefulness for Controlling Aging
Current Aging Science Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Graves Ophthalmopathy: A Review of Immunogenetics
Current Genomics Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Development of MatLab Coding for Early Detection of Leukemia through Automated Analysis of RBCs
Current Cancer Therapy Reviews Systems Biology and Computer-Aided Drug Discovery
Current Computer-Aided Drug Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Patent Selections
Recent Patents on Drug Delivery & Formulation Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins
Current Nanoscience Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Recent Progress in Chemosensors Using Aldehyde-bearing Fluorophores for the Detection of Specific Analytes and their Bioimaging
Current Medicinal Chemistry Von Hippel-Lindau Disease
Current Molecular Medicine An Uncommon Case of Symptomatic Multiple Meningiomas with Bilateral Compressive Optic Neuropathy Rapidly Induced under Cyprotero ne Acetate Treatment
Current Drug Safety